Genentech

SUSVIMO

Manufacturer:

Genentech

Susvimo HCPCS:

J2779

HCPCS Code Descriptor:

Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg

Category:

J Code

Susvimo NDCs:

50242-0078-55, 50242-0078-12

Primary Type:

Opthalmic

Generic/Specialty Status:

Single-Source

Package Type:

Multiple

Route of Administration:

Intraocular

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

50242-0078-55, 50242-0078-12

About Susvimo:

SUSVIMO is an Opthalmic drug manufactured by Genentech and administered via the Intraocular route of administration. The J Code: J2779 is aligned to the drug SUSVIMO.

ACCESS PRICING AND MORE BY REGISTERING

J2779 Added Date:

July 1, 2022

J2779 Effective Date:

July 1, 2022

J2779 Termination Date:

HCPCS Active

Susvimo billing and coding information can be found through Genentech at the link below:
Susvimo patient assistance information can be found through Genentech at the URL: https://www.gene.com/patients/patient-foundation
SUSVIMO prescribing information can be found at the link below:
Information regarding SUSVIMO’s side effects can be found at MedlinePlus